324 related articles for article (PubMed ID: 12588361)
1. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation.
Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Kwon SW; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Br J Haematol; 2003 Feb; 120(4):702-10. PubMed ID: 12588361
[TBL] [Abstract][Full Text] [Related]
2. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
[TBL] [Abstract][Full Text] [Related]
3. Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.
Chung HJ; Lee JH; Kwon SW
J Clin Lab Anal; 2008; 22(6):383-90. PubMed ID: 19021268
[TBL] [Abstract][Full Text] [Related]
4. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.
Tomac G; Bojanić I; Mazić S; Vidović I; Raos M; Ćepulić BG; Seiwerth RS; Kelečić J; Labar B
Blood Transfus; 2018 Jul; 16(4):397-404. PubMed ID: 28488966
[TBL] [Abstract][Full Text] [Related]
5. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
6. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
Stussi G; Halter J; Bucheli E; Valli PV; Seebach L; Gmür J; Gratwohl A; Schanz U; Passweg JR; Seebach JD
Haematologica; 2009 Feb; 94(2):239-48. PubMed ID: 19144657
[TBL] [Abstract][Full Text] [Related]
7. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Zhu KE; Li JP; Zhang T; Zhong J; Chen J
Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
[TBL] [Abstract][Full Text] [Related]
10. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
11. [Pure red cell aplasia following ABO-incompatible allogeneic hematopoietic stem cell transplantation].
Fan H; Jing Y; Li HH; Lu XC; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):364-7. PubMed ID: 18426666
[TBL] [Abstract][Full Text] [Related]
12. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.
Curley C; Pillai E; Mudie K; Western R; Hutchins C; Durrant S; Kennedy GA
Transfusion; 2012 Feb; 52(2):291-7. PubMed ID: 21848968
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO-incompatible hematopoietic stem cell transplant.
Vivero A; Peedin AR; Gao Y; Karp JK
J Clin Apher; 2023 Aug; 38(4):495-499. PubMed ID: 36703597
[TBL] [Abstract][Full Text] [Related]
15. Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Zhu KE; Xu Y; Wu D; Zhong J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Feb; 10(1):61-5. PubMed ID: 12513840
[TBL] [Abstract][Full Text] [Related]
16. Characterization of reemergent anti-B red blood cell antibodies in a patient with recurrent acute myeloid leukemia with ABO-incompatible allogeneic peripheral blood stem cell transplantation.
Tajima K; Takizawa K; Yasuda T; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Okumura W
Transfusion; 2019 Nov; 59(11):3319-3323. PubMed ID: 31503348
[TBL] [Abstract][Full Text] [Related]
17. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
Bolan CD; Leitman SF; Griffith LM; Wesley RA; Procter JL; Stroncek DF; Barrett AJ; Childs RW
Blood; 2001 Sep; 98(6):1687-94. PubMed ID: 11535498
[TBL] [Abstract][Full Text] [Related]
18. [ABO-incompatible nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Sun WJ; Guo M; Qiao JH; Yu CL; Wang DH; Sun QY; Zhang S; Li X; Ai HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):39-42. PubMed ID: 15748433
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation.
Zhu P; Wu Y; Cui D; Shi J; Yu J; Zhao Y; Lai X; Liu L; Xie J; Huang H; Luo Y
Front Immunol; 2022; 13():829670. PubMed ID: 35222414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors.
Hirokawa M; Fukuda T; Ohashi K; Hidaka M; Ichinohe T; Iwato K; Kanamori H; Murata M; Sakura T; Imamura M; Adachi S; Suzuki R; Morishima Y; Sakamaki H;
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1026-32. PubMed ID: 23583828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
